BioSpace News Archive

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that the Company will be presenting mechanism of action findings and study design details at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium taking place February 28 to March 2 in San Francisco, CA.

Evofem Biosciences, Inc.,, a clinical stage biopharmaceutical company, reported financial results for the three- and twelve- month periods ended December 31, 2018.

ImmunoGen, Inc. announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress at The ASCO-SITC Clinical Immuno-Oncology Symposium.

MaxCyte, the global cell-based medicines and life sciences company, announced that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement.

Interim Data Analysis from 8 mg Twice-Daily Cohort of Investigational CTP-543 Showed Statistically Significant Effect on Primary Endpoint in Patients with Moderate-to-Severe Alopecia Areata

Endo International plc (NASDAQ: ENDP) today announced that it will present new data showing collagenase clostridium histolyticum (CCH) significantly met the clinical endpoint of improved cellulite severity and appearance and was well tolerated in recent Phase 3 clinical trials.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events:

More than 40 percent of Americans are myopic and that number is increasing at an alarming rate, especially among school-aged children.

When Tough Mudder approached digital streaming platform Openfit to create a comprehensive branded workout and nutrition program, there were two important questions: Who would lead the 30-day body-transformation and event-prep program, and how would Tough Mudder capture the same sense of teamwork and accomplishment that made it the leading obstacle course event series in the world?